A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Treatment‐Experienced Patients Infected with Non‐R5 HIV‐1
The Journal of Infectious Diseases2009Vol. 199(11), pp. 1638–1647
Citations Over TimeTop 10% of 2009 papers
Michael S. Saag, James Goodrich, Gerd Fätkenheuer, Bonaventura Clotet, Nathan Clumeck, John F. Sullivan, Mike Westby, Elna van der Ryst, Howard Mayer, A4001029 Study Group
Abstract
Clinicaltrials.gov identifier NCT00098748 .
Related Papers
- → Rapamycin enhances aplaviroc anti-HIV activity: Implications for the clinical development of novel CCR5 antagonists(2009)15 cited
- → Maraviroc: A Ccr5 Antagonist(2008)2 cited
- → New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists(2008)15 cited
- → Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention(2011)12 cited